Danaher Co. (NYSE:DHR) Shares Purchased by Delaney Dennis R

Delaney Dennis R increased its holdings in Danaher Co. (NYSE:DHR) by 0.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,863 shares of the conglomerate’s stock after purchasing an additional 100 shares during the quarter. Danaher accounts for about 3.2% of Delaney Dennis R’s holdings, making the stock its 14th largest holding. Delaney Dennis R’s holdings in Danaher were worth $5,962,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at about $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the first quarter valued at approximately $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Robert W. Baird increased their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Barclays lifted their price objective on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Finally, Evercore ISI cut their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

Danaher Stock Down 0.2 %

DHR opened at $271.90 on Thursday. The company has a market cap of $201.39 billion, a price-to-earnings ratio of 46.08, a PEG ratio of 4.48 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business’s fifty day moving average is $266.50 and its two-hundred day moving average is $256.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the firm earned $2.05 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. Analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.